Rhinosinusitis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Rhinosinusitis – Drugs In Development, 2024 report and make more profitable business decisions.
Rhinosinusitis is a condition that affects the nasal and sinus mucosa, causing inflammation and symptoms such as nasal congestion, discharge, pain, and loss of smell. It can be classified into acute or chronic, depending on the duration of the illness. Acute rhinosinusitis usually lasts less than four weeks and is often caused by viral or bacterial infections. Chronic rhinosinusitis lasts more than 12 weeks and is often associated with allergies, nasal polyps, deviated septum, or fungal infections. Rhinosinusitis can be diagnosed by history, physical examination, and sometimes by nasal or sputum culture or CT scan. Treatment options include pain relievers, decongestants, nasal irrigation, topical steroids, antibiotics, and surgery in some cases. Rhinosinusitis can affect the quality of life and lead to complications such as sleep apnea and orbital or intracranial infections if left untreated.
The Rhinosinusitis drugs in development market research report provide comprehensive information on the therapeutics under development for Rhinosinusitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rhinosinusitis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Rhinosinusitis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 35 molecules, with 35 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Rhinosinusitis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Rhinosinusitis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Rhinosinusitis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
3SBio IncABT Innovations Inc
Amgen Inc
AstraZeneca Plc
Celltrion Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Diceros Therapeutics Inc
GeneOne Life Science Inc
Genrix (Shanghai) Biopharmaceutical Co Ltd
GlycoMira Therapeutics Inc
GSK plc
Insmed Inc
Jiangsu Hengrui Medicine Co Ltd
JiangSu Qyuns Therapeutics Co Ltd
JSR Life Sciences LLC
KeyMed Biosciences Inc
Lanier Biotherapeutics Inc
LianBio
Luye Pharma Group Ltd
Lyra Therapeutics Inc
Maxwell Biosciences Inc
MD Healthcare Inc
OptiNose Inc
Oticara Inc
Pfizer Inc
Pleros Therapeutics Inc
Recce Pharmaceuticals Ltd
Regeneron Pharmaceuticals Inc
Sanofi
SaNOtize Research and Development Corp
Shanghai JMT-Bio Technology Co Ltd
Synermore Biologics Co Ltd
Trellis Bioscience LLC
Upstream Bio Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Rhinosinusitis reports